Las Vegas, NV -- (SBWIRE) -- 01/04/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: Medbox Inc(OTCMKTS:MDBX), Federal Home Loan Mortgage Corp(OTCBB:FMCC), Cannabis Science Inc(OTCMKTS:CBIS), Provectus Pharmaceuticals, Inc.(OTCMKTS:PVCT)
Medbox Inc(OTCMKTS:MDBX) increased 6.56% at the price of $26.32recently on a traded volume of 117,505.00 shares, in comparison to 46,912.00 shares of average trading volume. So far this year, the stock is up over 44.14%.
The company has a total market capitalization of $364.32 million. Medbox Inc. (Medbox) offers a machine that dispenses medication to individuals based on biometric identification (fingerprint sample). The machine allows pharmacies, hospitals, doctors' offices, and alternative medicine clinics to manage employee possession of sensitive drugs.
For How Long MDBX will Fight for Profitability? Read This Trend Analysis report
Federal Home Loan Mortgage Corp(OTCBB:FMCC) plunged -1.04% at the trading price of $2.85 on a traded volume of 1.17 million shares till now, whereas its average trading volume is 8.82 million shares. In the last three months, the stock is up 102.84%. The Intra-day range for the stock is $0.28 and $5.00. Federal Home Loan Mortgage Corporation (Freddie Mac) conducts business in the United States residential mortgage market and the global securities market. The Company operates in three segments: Single-family Guarantee, Investments, and Multifamily. The Single-family Guarantee segment reflects results from the Company's single-family credit guarantee activities
Has FMCC Found The Bottom And Ready To Gain Momentum? Find Out Here
Cannabis Science Inc(OTCMKTS:CBIS) dropped down -19.90% at the $0.0640 recently. So far in three months, the stock is up +48.24%. The 52-week range for the stock is $0.03 and $0.12. Its introductory price for the day was $0.09, with the overall traded volume of 57.29 million shares. Cannabis Science, Inc. is a development-stage company. Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. The Company is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance
Why Should Investors Buy CBIS After the Recent Fall? Just Go Here and Find Out
Provectus Pharmaceuticals, Inc.(OTCMKTS:PVCT), after opening its shares at the price of $2.98, jumped up 8.09% , its recent trading price was $2.94 for the day. The stock moved on a traded volume of 1.13million shares, in comparison to 1.56 million shares of average trading volume. The 52-week range for the stock is $0.55 and $3.00. Its introductory price for the day was $2.98. Provectus Pharmaceuticals, Inc. is a development-stage pharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company develops and focuses to license or market and sells its two prescription drug candidates, PV-10 and PH-10.
Why Should Investors Buy PVCT After The Recent Gain? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/disclaimer-2/
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)